RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals"For 2022, the average among the five largest deals presently stands at $10.5 billion.
That's up from the $6.4 billion in 2021.
In short, this year’s pharma M&A activity was characterized by a sizable uptick in the number of buyouts and a modest increase in the average deal size on the top end of the spectrum relative to 2021."